Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to ...
Opinion
20don MSNOpinion
Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors
Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.
The exercise is simple: how large a position in Bristol Myers Squibb (NYSE:BMY | BMY Price Prediction) do you need to throw ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Bristol Myers Squibb is one of the world's largest pharmaceutical companies. The sector is very competitive, and the cost of developing novel drugs is extremely high. That said, Bristol Myers Squibb ...
Bristol-Myers Squibb is upgraded to Buy as its growth portfolio now offsets legacy declines, validating a bullish contrarian thesis. BMY's 2026 guidance and Q4 2025 results exceeded consensus, with ...
Hosted on MSN
Jim Cramer senses a 'fake out' in rumored AstraZeneca, Bristol Myers Squibb $400 billion mega-merger
CNBC’s Jim Cramer has cast doubt on reports surrounding a potential $400 billion merger between pharmaceutical heavyweights AstraZeneca PLC AZN and Bristol-Myers Squibb Co. BMY. Reacting to reports of ...
CEO Christopher Boerner opened by highlighting, “2025 was a year of focused execution across the business. We believe our results further demonstrate the ongoing strength in our growth portfolio as we ...
Proposed $400bn tie-up with Bristol Myers Squibb would create world’s fourth-largest drugmaker but analysts question rationale ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results